CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 273 enrolled
Drug / intervention
Blood withdrawalother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06847100
NCT06847100N/ACompleted

Development of Artificial Intelligence Models to Predict Intrahospital Atrial Fibrillation and Long-term Coronary Event Recurrence in High-risk Patients: PerCard Study

Centro Cardiologico Monzino·observational·Posted Feb 26, 2025·Updated Aug 26, 2025

In Brief

An observational study evaluating Blood withdrawal for Atrial Fibrillation. Completed, enrolled 273 participants across 4 sites in 3 countries.

Detailed Summary

Atrial fibrillation (AF) is a frequent and clinically relevant problem among the events that may occur during the hospitalization period in patients with cardiovascular disease. AF, indeed, is a determinant or aggravating condition of serious adverse events, such as myocardial infarction, heart failure, and thromboembolic stroke. The occurrence of AF in hospitalized patients, such as those admitted for coronary intervention, results in prolonged length of hospitalization, increased likelihood of discharge on anticoagulants, and increased 30-day risk of bleeding. It is noteworthy that while the incidence of AF in the general population is about 1-2 cases per 1000 people per year, this is much higher in patients hospitalized for acute myocardial infarction (AMI) (about 10% over the hospitalization period) or in patients undergoing coronary artery bypass grafting (CABG) (about 25% over the hospitalization period). Thus, identifying patients at high risk of AF during the hospitalization period could allow experimental testing of the efficacy and safety of preventive interventions (e.g., tailored anesthetic or surgical approaches, drug-prevention, etc.). It can be hypothesized that the clinical and nonclinical variables useful in estimating the risk of AF will change depending on the type of patients and that the identification and integration of these variables will require more complex predictive analysis systems than the regression models classically used to develop risk scores. On the other hand, the risk of recurrence of coronary events throughout the first years after CABG remains high (about 20% at 5 years) despite effective revascularization and early secondary prevention.Although some scores have been developed for estimating the risk of coronary event recurrence in secondary prevention using multivariate regression models, these algorithms consider a limited number of predictors, do not take into account possible interactions between different factors, and their actual predictive ability is not reported in the literature. With advances in Artificial Intelligence (AI) technology together with the rapid development of digital clinical datasets, machine learning has the potential to analyze substantial amounts of data and recognize patterns to predict AF onset and recurrence of coronary events within a defined time horizon (e.g., in-hospital event) in selected populations in a way that improves the predictive ability of conventional methods.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesFinland, Germany, Italy

Timeline

N/ACompletedFinished
202420252026
First PostedFeb 26, 2025
Enrollment StartFeb 6, 2023
Primary CompletionJun 30, 2025
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 1.3 years ago

Interventions

Blood withdrawalother

Optional collection of 5 mL of blood to assess the contribution of 16 gene polymorphisms AF-associated